Compare IRIX & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRIX | KALA |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 13.3M |
| IPO Year | 1996 | 2017 |
| Metric | IRIX | KALA |
|---|---|---|
| Price | $0.62 | $0.48 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 44.3K | ★ 298.9K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.85 | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,593,000.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.61 | $0.07 |
| 52 Week High | $1.65 | $3.96 |
| Indicator | IRIX | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 35.57 |
| Support Level | $0.61 | $0.35 |
| Resistance Level | $0.98 | $0.61 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 27.74 | 35.01 |
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.